Diadem Digital Solutions LLC
1010 Naughton Drive
5 articles with Diadem Digital Solutions LLC
Sanofi, AstraZeneca, Avillion and Diadem recently announced clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.
Following the decision to limit the coverage of Biogen’s controversial Alzheimer’s drug Aduhelm, the Alzheimer’s community is now waiting for other companies to deliver new therapies.
Esai, Biogen, Diadem and ProMis all presented their findings on biomarker research at this year's International Conference on Alzheimer's and Parkinson's Diseases.
Diadem Presents Clinical Validation Interim Data Confirming Its AlzoSure® Prognostic Biomarker Test Accurately Predicts Progression to Alzheimer's Disease
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer's disease, announced top-line interim results from a global clinical validation study of its AlzoSure® Predict prognostic biomarker test, which can accurately predict progression to Alzheimer's disease years before symptoms appear.